SML0116

GW788388 Hydrate

≥98% (HPLC)

• Synonym(e): 4-{4-[3-(Pyridin-2-yl)-1H-pyrazol-4-yl]-pyridin-2-yl}-N-(tetrahydro-2H-pyran-4-yl)benzamide hydrate
• Empirische Formel (Hill-System): C₂₅H₂₃N₅O₂ · xH₂O
• Molekulargewicht: 425.48 (anhydrous basis)
• MDL-Nummer: MFCD20527321
• UNSPSC-Code: 12352200
• PubChem Substanz-ID: 329825168
• NACRES: NA.77

Eigenschaften

• Qualitätsniveau: 100
• Assay: ≥98% (HPLC)
• Form: powder
• Farbe: white to tan
• Löslichkeit: DMSO: ≥8 mg/mL
• Ersteller: GlaxoSmithKline
• Lagertemp.: 2-8°C
• SMILES String: O.O=C(NC1CCOCC1)c2ccc(cc2)-c3cc(ccn3)-c4c[nH]nc4-c5ccccn5
• InChI: 1S/C25H23N5O2.H2O/c31-25(29-20-9-13-32-14-10-20)18-6-4-17(5-7-18)23-15-19(8-12-27-23)21-16-28-30-24(21)22-3-1-2-11-26-22;/h1-8,11-12,15-16,20H,9-10,13-14H2,(H,28,30)(H,29,31);1H2
• InChIKey: VZRJMBZMFKADGR-UHFFFAOYSA-N

Beschreibung

Biochem./physiol. Wirkung

GW788388 is a potent selective inhibitor of TGF-beta type I receptor [activin receptor-like kinase 5 (ALK5)]. GW788388 is orally available with a half-life of approximately 4 hours.

TGFβ1 (ALK5) inhibitor; Potent, selective inhibitor of TGFβ signalling in vitro and renal fibrosis in vivo

Leistungsmerkmale und Vorteile

This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Sicherheitshinweise

• Piktogramme: GHS06,GHS09
• Signalwort: Danger
• H-Sätze: H301,H400
• P-Sätze: P273 - P301 + P310 + P330
• Gefahreneinstufungen: Acute Tox. 3 Oral - Aquatic Acute 1
• Lagerklassenschlüssel: 6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
• WGK: WGK 3
• Flammpunkt (°F): Not applicable
• Flammpunkt (°C): Not applicable